The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces tiny amounts of hydrogen sulfide in healthy brain cells. Mice genetically ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...